ALEC News and Press, Alector Inc. From 01/19/24

SOUTH SAN FRANCISCO, Calif., Jan. 19, 2024 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced the closing of its underwritten public offering of shares of its common stock. Alector sold 10,869,566 shares of its com...

2024-01-17 17:32:22 ET Summary Alector, Inc. expects results from its phase 2 INVOKE-2 study, using AL002 for the treatment of patients with Alzheimer's disease, in Q4 of 2024. IND clearance received to begin a phase 2 study using AL101 for the treatment of patients with Alzheimer...

2024-01-17 09:37:51 ET More on Alector Alector: Good Data, Huge Cash, No Near Term Catalyst Stifel upgrades Alector to buy, stock rallies 18% Alector GAAP EPS of -$0.53 beats by $0.14, revenue of $9.11M misses by $0.86M For further details see: Alector do...

SOUTH SAN FRANCISCO, Calif., Jan. 17, 2024 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced the pricing of an underwritten public offering of 10,869,566 shares of its common stock for total gross proceeds of $75 ...

2024-01-16 16:05:26 ET More on Alector Stifel upgrades Alector to buy, stock rallies 18% Alector GAAP EPS of -$0.53 beats by $0.14, revenue of $9.11M misses by $0.86M For further details see: Alector intends to conduct a public offering of its shares

2024-01-16 11:12:10 ET Summary Alector's stock has traded mostly sideways, down 18% from last year, despite having a promising late-stage CNS pipeline, loads of cash, and two big partnerships. The company has trimmed down its pipeline from 9 programs to 3, but this is a good thing...

2023-12-14 15:01:02 ET More on Alector Alector: Milestone Uncertainty Plus Lack Of Product Revenue Alector GAAP EPS of -$0.53 beats by $0.14, revenue of $9.11M misses by $0.86M Alector achieves target enrollment for Phase 3 dementia study Seeking Alpha’...

2023-12-14 10:00:03 ET More on Health Care Select Sector SPDR Ideal Pairs Trade Into 2024: Health Vs. Hype: Capitalizing On A Therapeutic Turn And A Tech Tumble Health Care Select Sector Fund ETF: Riding The Healthcare Boom For further details see: Ocular Therape...

SOUTH SAN FRANCISCO, Nov. 28, 2023 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced management will host two virtual events in December to discuss the Company’s TREM2 and progranulin (PGRN) programs. The e...

SOUTH SAN FRANCISCO, Calif., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced management will participate in a fireside chat at the Stifel Healthcare Conference on Tuesday, November 1...